eEF1A2 as a Putative Oncogene

Abstract

The first evidence for the role of the protein elongation factor eEF1A2 in tumorigenesis was reported by Anand and colleagues who demonstrated that eEF1A2 is overexpressed in about 30% of ovarian tumors and some established ovarian cancer cells. This abnormal expression correlates with a poor prognosis. Since this discovery, there have been several reports suggesting eEF1A2 as a diagnostic marker in various cancers. This review highlights the oncogenic potential of eEF1A2.

Overexpression of eukaryotic elongation factor 1 alpha-2 is associated with poorer prognosis in patients with gastric cancer

“…These results suggested potentially promising usefulness of eEF1A2 as a prognostic indicator. Consistent with our findings, previous reports expound that eEF1A2 was overexpressed in various cancers (Lee and Surh 2009), and it has been reported to be closely related to cancer development and poor survival, especially in pancreatic cancer (Duanmin et al 2013) and lung cancer (Li et al 2006). eEF1A genes encode essential factors in translation elongation and are potentially involved in tumorigenesis of certain kinds of human cancers (Anand et al 2002;Chen and Madura 2005;Li et al 2006;Tomlinson et al 2005).…”

“…Importantly, eEF1A2 was considered as a putative oncogene because of its ectopic expression in several kinds of cancer. The expression of EEF1A2 in non-special tissues has been reported to be associated with cancer development and invasion in ovarian, breast, lung, prostate, hepatic, and pancreatic cancers (Lee and Surh 2009). As upregulation of eEF1A2 was associated with perineural invasion, lymph node metastasis and poorer prognosis (Duanmin et al 2013), it suggested a potential role of eEF1A2 in tumor progression and metastasis.…”

Protumorigenic role of Timeless in hepatocellular carcinoma

“…The eukaryotic elongation factor 1-α (EEF1A), a member of the G protein family, represents one of the four subunits that constitute the eukaryotic elongation factor 1 (16). In humans, zation; atm, ataxia telangiectasia mutated; aKt, v-akt murine thymoma viral oncogene homolog; cDna, complementary Dna; cheK1, checkpoint kinase 1; cheK2, checkpoint kinase 2; chX, cycloheximide; csnK1e, casein kinase 1ε; ctrl, negative control; Dna, deoxyribonucleic acid; eeF1a2, eukaryotic elongation factor 1a2; fw, forward; hBV, hepatitis B virus; hcV, hepatitis c virus; hcc, hepatocellular carcinoma; IP, immunoprecipitation; mDm2, mouse double minute homolog 2; mDm4, mouse double minute homolog 4; mtoR, mammalian target of rapamycin; nl, normal liver; oF, oligofectamine control; p21, cyclin-dependent kinase inhibitor 1a (cDKn1a, cip1); p53, tumor protein p53; PI3K, phosphoinositide-3-kinase; Page, polyacrylamide gel electro phoresis; PeR1, period circadian clock 1; PeR2, period circadian clock 2; Pt, peritumorous, non-neoplastic liver tissue; PUma, Bcl2 binding component 3; qRt-PcR, quantitative real-time polymerase chain reaction; Rna, ribonucleic acid; RoRa, RaR-related orphan receptor a; rev, reverse; sDs, sodium dodecyl sulfate; sem, standard error of the mean; sinc, non-target control siRna; siRna, short interfering Rna; sitIm, siRna targeting timeless; tIm, timeless; tIPIn, tImeless interacting protein; tma, tissue microarray; WB, western immunoblotting two EEF1A isoforms are known.…”

Translational Control in Tumour Progression and Drug Resistance

“…In humans, eEF1A2 shows oncogenic properties when over-expressed; moreover, it is implicated in ovarian, breast, pancreatic, liver and lung cancer thus becoming one of the most intriguing putative oncogenes in the last decade [82]. Notably, eEF1A2 can either directly or indirectly activate the Akt signalling pathway.…”